Archive by category | Publishing

Climate comments push open-access publisher to terminate journal

A German academic publisher that has journals of respected scientific societies among its titles has announced that it shut down its journal Pattern Recognition in Physics, citing what it calls nepotistic reviewing and malpractice. The firm, Copernicus Publishing of Göttingen, Germany, was responding to a recent special issue on ‘solar variability’. “The special issue editors ultimately submitted their conclusions in which they ‘doubt the continued, even accelerated, warming as claimed by the IPCC project’,” the publisher wrote in its statement.  Read more

Court upholds need for export permits for risky flu research

The researcher who created mammalian-transmissible strains of the H5N1 avian flu virus, raising fears they could cause a pandemic, has failed in an attempt to overcome government restrictions on the publication of his papers. See Nature News Mutant Flu special  … Read more

European Research Council funds arXiv — a taste of changes to come

European Research Council funds arXiv — a taste of changes to come

The European Research Council (ERC) announced today that it has joined the list of more than 170 institutions to financially support arXiv, the major online repository for pre-print papers operated by Cornell University Library in Ithaca, New York.  Read more

Japan investigations allege misconduct in large-scale clinical studies

The credibility of Japan’s clinical research system has come under fire as investigations report manipulation of data and conflict of interest involving the pharmaceutical company Novartis. Six published papers have been retracted, but Novartis has denied any wrongdoing. The country’s health minister has now started its own investigation, which is due to release its findings at the end of September.  Read more

Pharma industry moves towards greater openness

The pharmaceutical industry has signalled its willingness to open up the vast reservoirs of research data held by its companies this week. But campaigners and researchers pushing for more access to clinical trial data say the moves are little and late.  Read more